B of A Securities Downgrades IGM Biosciences to Neutral, Announces $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham downgraded IGM Biosciences (NASDAQ:IGMS) from Buy to Neutral and set a price target of $8.
December 15, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IGM Biosciences was downgraded by B of A Securities from Buy to Neutral with a price target of $8.
Downgrades by analysts can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The new price target of $8 may also set a lower expectation for the stock's future performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100